These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 38660357)

  • 41. Universal screening for social determinants of health in pediatric sickle cell disease: A quality-improvement initiative.
    Power-Hays A; Li S; Mensah A; Sobota A
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28006. PubMed ID: 31571379
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.
    Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M
    Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.
    Chan WK; Chuah KH; Rajaram RB; Lim LL; Ratnasingam J; Vethakkan SR
    J Obes Metab Syndr; 2023 Sep; 32(3):197-213. PubMed ID: 37700494
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
    Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
    Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort.
    Ossima AN; Brzustowski A; Paradis V; Van Beers B; Postic C; Laouénan C; Pol S; Castéra L; Gautier JF; Czernichow S; Vallet-Pichard A; Larger E; Serfaty L; Zins M; Valla D; Zaleski ID
    Clin Diabetes Endocrinol; 2024 Apr; 10(1):9. PubMed ID: 38659082
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Developing a Social Determinants of Health Needs Assessment for Colorado Kids (SNACK) Tool for a School-Based Asthma Program: Findings from a Pilot Study.
    Brewer SE; DeCamp LR; Reedy J; Armstrong R; DeKeyser HH; Federico MJ; McFarlane A; Figlio G; Huebschmann AG; Szefler SJ; Cicutto L
    Ethn Dis; 2023 Dec; DECIPHeR(Spec Issue):126-131. PubMed ID: 38846737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
    Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
    Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Social determinants of health and US cancer screening interventions: A systematic review.
    Korn AR; Walsh-Bailey C; Correa-Mendez M; DelNero P; Pilar M; Sandler B; Brownson RC; Emmons KM; Oh AY
    CA Cancer J Clin; 2023; 73(5):461-479. PubMed ID: 37329257
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
    Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
    JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fatty Liver Disease: Enter the Metabolic Era.
    Wegermann K; Moylan C; Naggie S
    Curr HIV/AIDS Rep; 2023 Dec; 20(6):405-418. PubMed ID: 37882965
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of an Integrated Intervention to Address Clinical Care and Social Needs Among Patients with Type 2 Diabetes.
    Roth SE; Gronowski B; Jones KG; Smith RA; Smith SK; Vartanian KB; Wright BJ
    J Gen Intern Med; 2023 Mar; 38(Suppl 1):38-44. PubMed ID: 36864267
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Screening for the social determinants of health: Referring patients to community-based services.
    Mullen LG; Oermann MH; Cockroft MC; Sharpe LM; Davison JA
    J Am Assoc Nurse Pract; 2023 Dec; 35(12):835-842. PubMed ID: 37471525
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of a social determinants of health screening questionnaire and workflow pilot within an adult ambulatory clinic.
    Berkowitz RL; Bui L; Shen Z; Pressman A; Moreno M; Brown S; Nilon A; Miller-Rosales C; Azar KMJ
    BMC Fam Pract; 2021 Dec; 22(1):256. PubMed ID: 34952582
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians.
    Wu T; Ye J; Mo S; Ye M; Li X; Li Q; Wang W; Zheng Q; Luo K; Zhang Y; Tu S; Che D; Gong R; Chen X; Miu R; Shao C; Sun Y; Zhong B
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1636-1647. PubMed ID: 38695344
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
    Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
    J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Social Determinants of Health: What Are They and How Do We Screen.
    Johnson CB; Luther B; Wallace AS; Kulesa MG
    Orthop Nurs; 2022 Mar-Apr 01; 41(2):88-100. PubMed ID: 35358126
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glucagon-like Peptide-1 Receptor Agonists-A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Choi E; Ramirez Tovar A; He Z; Soler Rodriguez DM; Vos MB; Arora S; Fadoju D
    Children (Basel); 2024 Feb; 11(3):. PubMed ID: 38539310
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Social Determinants of Health and Cardiovascular Disease: Current State and Future Directions Towards Healthcare Equity.
    Jilani MH; Javed Z; Yahya T; Valero-Elizondo J; Khan SU; Kash B; Blankstein R; Virani SS; Blaha MJ; Dubey P; Hyder AA; Vahidy FS; Cainzos-Achirica M; Nasir K
    Curr Atheroscler Rep; 2021 Jul; 23(9):55. PubMed ID: 34308497
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of Social Determinants of Health on Heart Failure Outcomes: A Systematic Review.
    Enard KR; Coleman AM; Yakubu RA; Butcher BC; Tao D; Hauptman PJ
    J Am Heart Assoc; 2023 Feb; 12(3):e026590. PubMed ID: 36695317
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of Social Determinants of Health and Their Cumulative Impact on Hospitalization Among a National Sample of Community-Dwelling US Adults.
    Wray CM; Tang J; López L; Hoggatt K; Keyhani S
    J Gen Intern Med; 2022 Jun; 37(8):1935-1942. PubMed ID: 34355346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.